Insider Selling: Roivant Sciences (NASDAQ:ROIV) Insider Sells 172,899 Shares of Stock

Key Points

• Insider selling: Mayukh Sukhatme sold 172,899 Roivant Sciences shares for approximately $6.43 million at an average price of $37.17, reducing his ownership by 0.92% to 18.63 million shares. He also reported several other sales during the same week.
• Stock performance and results: ROIV recently traded at $36.30, down 1.5%, near its 52-week high of $37.97. The company posted a quarterly loss of $0.26 per share, beating estimates, but revenue of $1.44 million fell short of expectations.
• Investor sentiment: Institutional investors own 64.76% of Roivant’s stock, while analysts maintain a “Moderate Buy” consensus rating. Several firms recently raised their price targets, although the average target of $35.14 is below the reported share price.

Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) insider Mayukh Sukhatme sold 172,899 shares of the firm's stock in a transaction on Wednesday, August 19th. The stock was sold at an average price of $37.17, for a total value of $6,426,655.83. Following the transaction, the insider owned 18,630,739 shares of the company's stock, valued at approximately $692,504,568.63. This represents a 0.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Mayukh Sukhatme also recently made the following trade(s):

• On Friday, August 21st, Mayukh Sukhatme sold 144,756 shares of Roivant Sciences stock. The shares were sold at an average price of $36.48, for a total value of $5,280,698.88.
• On Thursday, August 20th, Mayukh Sukhatme sold 17,519 shares of Roivant Sciences stock. The stock was sold at an average price of $37.30, for a total value of $653,458.70.
• On Friday, August 14th, Mayukh Sukhatme sold 243,177 shares of Roivant Sciences stock. The shares were sold at an average price of $36.23, for a total value of $8,810,302.71.
• On Monday, August 17th, Mayukh Sukhatme sold 284,707 shares of Roivant Sciences stock. The shares were sold at an average price of $36.25, for a total value of $10,320,628.75.
• On Tuesday, August 18th, Mayukh Sukhatme sold 136,942 shares of Roivant Sciences stock. The shares were sold at an average price of $36.73, for a total value of $5,029,879.66.

Roivant Sciences Stock Down 1.5%

NASDAQ:ROIV traded down $0.54 on Friday, reaching $36.30. 6,185,493 shares of the company's stock were exchanged, compared to its average volume of 5,631,176. The firm has a market capitalization of $26.22 billion, a price-to-earnings ratio of -68.49 and a beta of 1.12. Roivant Sciences Ltd. has a 52-week low of $11.60 and a 52-week high of $37.97. The business has a fifty day moving average of $34.61 and a 200-day moving average of $30.43.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Friday, August 7th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.04. Roivant Sciences had a negative net margin of 3,534.96% and a negative return on equity of 22.94%. The business had revenue of $1.44 million during the quarter, compared to analyst estimates of $2.06 million. As a group, equities analysts anticipate that Roivant Sciences Ltd. will post -2 earnings per share for the current year.

Institutional Investors Weigh In On Roivant Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of ROIV. Goldman Sachs Group Inc. raised its stake in Roivant Sciences by 15.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company's stock valued at $24,553,000 after buying an additional 324,764 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of Roivant Sciences by 1.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company's stock worth $24,678,000 after acquiring an additional 34,341 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Roivant Sciences by 1.9% during the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company's stock worth $1,010,000 after acquiring an additional 1,689 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in shares of Roivant Sciences by 149.9% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company's stock valued at $129,000 after acquiring an additional 6,879 shares during the last quarter. Finally, M&T Bank Corp increased its holdings in shares of Roivant Sciences by 10.2% in the 2nd quarter. M&T Bank Corp now owns 12,802 shares of the company's stock valued at $144,000 after acquiring an additional 1,181 shares during the last quarter. 64.76% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Piper Sandler reaffirmed an "overweight" rating on shares of Roivant Sciences in a research report on Thursday, May 21st. TD Cowen reiterated a "buy" rating on shares of Roivant Sciences in a report on Thursday, August 6th. Guggenheim boosted their target price on Roivant Sciences from $36.00 to $42.00 and gave the stock a "buy" rating in a research note on Friday, August 7th. Bank of America restated a "neutral" rating on shares of Roivant Sciences in a report on Friday, July 31st. Finally, HC Wainwright lifted their price objective on Roivant Sciences from $34.00 to $41.00 and gave the company a "buy" rating in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $35.14.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source